1028
HLAVNÍ506722701005185134178232252
TÉMA533422701003981147194
SGLT-2385933701003782113146167200
inhibitory40753370100145290105143158185224248287
a4378337010034
jejich4428337010014496479110147
uplatnění45923370100367490125151189225263278
v4887337010035
praxi49383370100376197134150
–5104337010038
update515833701003775113148174209
2022538433701003375109143
|5584227010018
103561722701005398131
/35978043010757
Vnitř36738043010771118137165192
Lék.3884804301074184122140
2022;68(2):96-1034044804301074487128172187232277301343366380425469499537577619
/46828043010757
VNITŘNÍ47598043010792152173218266326347
LÉKAŘSTVÍ5126804301074285131189236281326379401
www.casopisvnitrnilekarstvi.cz42580430107651332012142542953293774274464795215705896176436927117307748128548809159449871007102310631101
ke42562301073882
snížení52862301074190109147191240259
mortality,808623010781131159191233253272301344357
úhrada1185623010756105132175225267
gliflozinů14726230107577696120144193229249298347
v1839623010748
indikaci190862301072675126145184227269288
léčby221762301072671113163204
chronického244162301074897124172222241283321366415464
onemocnění42576301074795138211258299346389437455
ledvin89976301071659108149168215
je113376301071659
tedy121176301072566116155
pouze138576301074695142178220
otázkou162576301074470111148185232279
času.192476301073677109155171
Revoluční211576301074185125171190237277324342
přínos24767630107467291138186219
SGLT2i27147630107389313316942590301074462
je50790301071862
proto58990301074976124151199
silně8089030107325170118163
vnímán99190301073989108182223271
nejen128290301074792111156204
diabetology,150690301074867108158203232279299347398439451
ale197790301074059103
i2101903010717
kardiology,213890301073780107155175223243292342383395
nefrology255390301074792116144192212261311352
a4251043010741
internisty.48610430107176593136162212231264293336349
U8551043010754
pacientů930104301074789130149194242270318
s12681043010732
diabetem1320104301074766107157202230273347
2.1688104301074257
typu1766104301072569120168
s19551043010731
klíčovými200610430107375876117164204248323342
komorbiditami2368104301073684159208235286305355374403444518537
(srdeční42511830107245682131175216265283
selhání,72811830107317695143184232251267
chronické1015118301073785112159208227267305349
onemocnění1384118301074594138212261302350395443462
ledvin,1866118301071660111152172220236
vysoké2122118301073881115164203246
a23881183010738
velmi2446118301073881101174193
vysoké2659118301073882116164203246
kardiovaskulární304762301073983110160180230271314349388438458500528578598
riziko)36666230107345593113152201224
musí3911623010782131166185
být411762301075899131
indikace426962301072776127147186230272316
gliflozinů46066230107577797122145195232252302351
s4978623010741
prokázanými504062301075886135175219258301351391468488
neglykemickými304776301074892143162202241284358377417455498573591
benefity365876301074792141185209229257300
zvažována397876301073478119157204244286334375
vždy437376301073876125165
bez455876301074792129
ohledu470776301074694114158208255
na498276301074687
kompenzaci508976301073582157206251300337379420439
diabetu,304790301074968109159204233281297
respektive336490301072973107156202240272291332376
hodnotu3760903010751100150199248275324
glykovaného410490301075271111151198239281330374423472
hemoglobinu,459690301075195169218269288337387407455503519
a5135903010744
glifloziny51999030107517190114137186221241289328
by3047104301074989
v31561043010737
takovém3213104301072567105152192235309
případě354210430107467392142184233277
měly38391043010770114134174
být4032104301074787118
preferovány4170104301074673116140184210257298339387426
nad4616104301074586135
antidiabetiky4771104301073886113132181200240289334362381419462
s52531043010731
pouze5303104301074796144181224
glykemickým3047118301074968109148191266285325364407482
působením.3549118301075099132181232277326344418435
LITERATURA426142001234978134189250318368438498567
1.42515800853647
Alberti4861581083405492126146169183
KGMM,68315810833475129183195
Zimmet89215810833650107163197218
PZ.11231581083357082
Definition,12181581083457995112148162183197234271282
diagnosis15141581083375181119156192218231256
and178415810833167105
classification19031581083304475100125139155172203234254268305342
of225915810833654
diabetes23271581083375182119154174207232
mellitus257315810835790104118132153189214
and280115810833168105
its4251682083153662
complications.50116820833469126164178192222254274288325362387399
Part9141682083376887111
1:103916820833643
Diagnosis10961682083486293130167204229243267
and137716820833471109
classification15001682083334778103128142158175206237257271308345
of185916820833957
diabetes19301682083415485123157178210236
mellitus.218016820835993107121134155192217229
Provisional24231682083385793123138162176212249280294
report27311682083235694131151175
of42517820833755
a494178208330
WHO538178208356100147
consultation.69917820832965102127163177198229249263300337349
Diabetic10621782083445888126160181195226
Medicine.130217820835386124138169182219253263
1998;15(7):539-553.15791782083336296129140169197214247265276309341373395428459490501
2.42518800853650
World48918820835691112126164
Health66618820834377107121142179
O.85918820834556
Global9291882083425793131163177
Report112018820833467105143163186
on132018820833673
Diabetes.14071882083445889126161181214239251
Global16721882083435794132164178
Report186418820833467105142163186
on206418820833673
Diabetes,21511882083445888126160181213239251
2016.24151882083336696126138
3.42519800853649
Nwaneri48819820834797128165199218233
CH73419820834285
Cooper,83319820834278115153188207216
Bowen‑Jones106319820833774124157194215234271308342367
D.144419820834858
Mortality151619820835693113136168182195216249
in177919820831653
type18461982083245694129
21989198208336
diabetes20391982083405484122156177209235
mellitus:228819820835993107121134155192217228
Magnitude253019820835688125162175197233271304
of284819820833957
the4252082083225892
evidence5312082083316176113147183214246
froma7912082083153672129171
systematic9762082083235480101134190221242255286
review1276208208317508195128178
andmeta‑analysis.146820820832965103171204225257278309345376390420446460484496
British1978208208332526788102126163
Journal21552082083205794114151182196
of236520820833452
Diabetes24302082083425787125159180212238
and268220820832865102
Vascular279820820833362884252182083316882112132
Disease.5712182083445883116147172206216
2013;13(4):192-207.8012182083336696125135163192209240256267295324356375404437468473
4.42522810853650
Cubbon48822820834277115153190227
RM72922820833791
et83422820833657
al.9052282083334759
Diabetes9772282083476192130164185217243
mellitus123422820835992106120134155191216
is146422820831641
associated15192282083335984121152166196217249287
with18202282083526687124
adverse195822820833371102135155181215
prognosis21862282083416197135171208234247272
in247222820831652
chronic25382282083337090125162176207
heart275922820833972103123146
failure425238108318506478114134167
of60623810834058
ischaemic6782381083194374111142175232246276
and96823810833672110
non‑ischaemic109223810834178115136151176207243274308364378409
aetiology.15142381083366990104141155192230261270
Diabetes17982381083496393131166186219244
and205623810833672110
Vascular21802381083396994125162176206226
Disease24202381083496388122152177211
Research.26452381083397398132162182212248260
2013;10(4):330-336.4252481083346797126136164195213244260271305336369392423454487499
5.42525800853649
MacDonald48825820835486116161198235266280317
MR81925820835489
et92225820833354
al.9902582083324657
Impact106125820831571109140171194
of126925820833755
diabetes13372582083385283120155175208233
on158425820833774
outcomes16722582083377495124160216250276
in196125820831551
patients20262582083387090104138174194221
with22612582083506485122
low239725820831451101
and251225820833168105
preserved26312582083395991117150170204236275
ejection4252681083344881113135149186223
fraction6622681083224374105128142178215
heart89126810834275106125149
failure1054268108322546781117137170
-1238268108324
An127626810834582
analysis137226810833572103117147173186211
of159726810834159
the16702681083256295
Candesartan177926810834475112150183209240260283315352
in214526810831854
Heart221326810834882112132155
failure:2382268108322546882118138170181
Assessment25772681083457297130156181237271308328
of42527810833857
Reduction49627810834075114152183207221259297
in80827810831956
Mortality87927810836098119143175190204226259
and115327810833674113
morbidity1280278108363101122161176215229251284
(CHARM)157927810832362106147182238255
programme.184927810834364101141161194252310345356
European22202781083377394130170205237274
Heart250927810834984115136160
Journal.268327810832967105125164196210222
2008;29(11):1377-1385.42528810833467102136146180213230261287300310339367398431448478506539572583
6.42529800853650
Matsushita48929820835384104131167191228242263294
K797298208333
et84429820833253
al.9112982083304455
Association9802982083396691128159173203224238274311
of130529820833553
estimated1372298208332588093150181201233272
glomerular16582982083365086143177197234248278298
filtration197029820831532466787118139153189226
rate22102982083195171103
and232729820833067104
albuminuria24452982083304482119175189225261281295326
with27852982083496384121
all‑cause425308208332465980113144180205239
and67830820833471108
cardiovascular8003082083346686122136173203235260291327341372392
mortality120530820836197118141172186200221253
in147230820831754
general154030820834174111145164196210
population176430820834179117154168198219233269306
cohorts:208430820833470107144164187213224
a2322308208335
collaborative2371308208334698498128166204224255276290321354
meta­273930820836093114146166
‑analysis.4253182083215288119133164189203227240
The67831820833270103
Lancet.7953182083306299129162183195
2010;375(9731):2073-2081.10033182083336696126138171202233250281312345375388398432465496529549579611645676684
7.42532800853643
Reidy4823282083367084121152
K648328208335
et69732820833455
al.7663282083334658
Molecular83832820835592106140171208221252272
mechanisms112432820835891123159190227241265321346
of148432820833856
Diabetic15543282083466091128163183197228
kidney17963282083304582119153183
disease.19933282083385277110141166200210
Journal22173282083256299118156187201
of243232820833755
Clinical25013282083415468104118149180194
Investigation.270932820831552821151401621764253382083386989103140177189
2014;124(6):2333-2340.6283382083326595125136164193223241273290300334367399431451481514548583594
8.42534800853650
Iborra‑Egea4893482083135088108128160181214251284315
O818348208344
et87634820833253
al.9433482083294355
Unraveling10123482083417897129159192206220256294
the13203482083195689
Molecular142334820835390104137169205219250270
Mechanismof170734820835285117153184221234259315364382
Action21033482083396991105142179
of229634820833553
Empagliflozin236334820833086124156193207221237254291317332368
in274534820831249
Heart2808348208342754253582083325275
Failure514358208336647791127147180
With7083582083617597133
Reduced85535820833973111147178210248
Ejection11173582083365083115137151188225
Fraction13563582083365486117139153190227
With15973582083617597133
or174435820834161
Without18193582083617697134171207229
Diabetes.20623582083486393131165186218244256
JACC233235820832866104141
Basic24873582083397095109139
Transl26403582083365284121145159
Sci.2813358208336678193
2019;4(7):831-840.4253682083346797126137171189222240251284317346363398433468479
9.42537810853648
Zinman4873782083405490146177214
B715378208337
et76637820833556
al.8363782083344759
Empagliflozin,90937820833490128160197211225241258295322336372384
cardiovascular13063782083336584121135172202234259290326340371391
outcomes,17103782083397697126162219253278290
and201437820833370107
mortality213537820835996116139171185198219252
in240137820831652
type24673782083245694129
22610378208335
diabetes.26593782083405484122156177209235247
New42538820834578128
England56738820833168105119150187224
Journal8053882083236096116153184198
of101738820833654
Medicine.108538820835387125139169183219253264
2015;373(22):2117-2128.13633882083326595124133167198231247280313330340374404430458475505535563596608
10.4253981085366882
Neal52139820834376107121
B656398208333
et70339820833152
al.7693982083294355
Canagliflozin83839820833769105136174188201218235271298312349
and120139820832966103
cardiovascular13183982083296180117131168198230255286322336367386
and171839820833066104
renal18363982083185188119133
events19823982083326396132153179
in217539820831249
type22373982083205291125
22376398208331
diabetes.24213982083365080118152173206231243
New267839820834276126
England2818398208330664254082083385283119157
Journal5964082083236096116153184198
of80840820833654
Medicine.87640820835387125138169183219253264
2017;377(7):644-657.11534082083336696124133166197230245278296307341376412433469501533538
11.4254181085366575
Wiviott51441820835974105119156177199
SD72741820833478
et81941820833556
al.8894182083334759
Dapagliflozin96241820834677115147184198212228245282308323359
and133541820833370108
cardiovascular14574182083326483120134170201233258289325339370389
outcomes18604182083397697126162219252278
in215241820831652
type22184182083235694128
22360418208336
diabetes.24104182083395384122156177209234247
New267041820834780130
England2814418208334704254282083385283119157
Journal5964282083236096116153184198
of80842820833654
Medicine.87642820835387125138169183219253264
2019;380(4):347-357.11534282083336696125136170203237255287303313347381412429460491523528
12.4254381085366781
Cannon52043820833970107144181218
CP75143820833973
et83843820833354
al.9054382083314556
Cardiovascular9754382083397190127141177208239265295332346377396
Outcomes138543820834683104133169226259285
with16844382083496384121
Ertugliflozin18194382083315174111148162176192209246273287323
in215643820831450
Type22204382083315896130
22364438208333
Diabetes.24114382083445889127161182214239252
New267743820834377126
England2817438208332684254482083385283119157
Journal5964482083236096116153184198
of80844820833654
Medicine.87644820835387125138169183219253264
2020;383(15):1425-1435.11534482083336697130142175208241257288316333344372402433466487517546577609620
13.4254580085356578
Perkovic5164581083306180109143173187216
V745458108331
et78945810833050
al.8524581083274051
Canagliflozin91645810833566101131167181193209226261287300336
and12654581083276399
renal13774581083164883113127
outcomes15174581083326888116151206239263
in179345810831146
type18524581083174886119
21984458108329
diabetes:20274581083334676112145165197221231
results22724581083164772107120140165
fromthe24504581083143469124155190223
CANVAS268645810833575117152188219
Program4254681083355490128147179235
randomised6744681083174884122158215229253287324
clinical1012468108328415591105135166180
trials.120646810831838528296120133
The135246810832967100
Lancet14664681083275996126158179
Diabetes16594681083415586123157178210235
and190846810832865102
Endocrinology.202446810832965102139170190204240277291328365396404
2018;6(9):691-704.24424681083316393123133168185216232243277309339357386418452463
14.4254780085366781
Neal52047810834478108122
B656478108334
et70447810833354
al.7724781083314556
Rationale,8424781083346686100137174205219252263
design11184781083387196110147184
and131647810833167105
baseline14354781083376994128142155192226
characteristics16744781083316798118149180203235255269294316330360387
of207547810833654
the21434781083205790
CANagliflozin224747810833981124155193207220237254290317331368
cardioVascular262947810833061811181321682012312564254881083316881112132
Assessment5714881083376389122147173229262299319
Study–Renal9044881083294885122153187223257293324338
(CANVAS‑R):12564881083155394138173210242263299316327
A1597488108337
randomized,16484881083174885122159216230257290328339
placebo‑controlled20014881083355080111143181218240272308345365385421435449482520
trial.253548810831838528397108
Diabetes,26574881083425686124158179211237248
Obesity42549810834785120145158179212
and65149810833067104
Metabolism.76949810835387108139177215229243267324335
2017;19(3):387-393.11184981083336696124133161190208240256266300333365382413445476487
15.4255080085366780
Neal51950820834275106120
B653508208332
et69950820833051
al.7645082083294354
Optimizing83250820834482103117173187215229265303
the11495082083185589
analysis12515082083296696110141166180205
strategy1470508208322446496116148187217
for17015082083155172
the17875082083185588
CANVAS188950820833778122157194227
Program:21305082083325187125145176233244
A2388508208337
prespecified24395082083355688114151185217230247264297335
plan27885082083365081118
for4255182083185575
the5145182083205790
integrated6185182083135070102140160192212245283
analyses9155182083306797111142167201226
of115551820833654
the12235182083205790
CANVAS132751820833980124159196229
and157051820833067105
CANVAS‑R168851820833980124159196229250286
trials.198851820832040548599124136
Diabetes,21385182083435888126160181213239251
Obesity240251820834684119144157178211
and262751820833067104
Metabolism.2745518208353871081394255282083397691104129185197
2017;19(7):926-935.6365282083336596124132161190207241259269303335367389422454485496
16.4255380085366882
Kosiborod5215382083387499113151188208244282
M817538208357
et88853820833758
al.9605382083344860
Lower103453820833470120153172
risk1220538208324386391
of132553820834058
heart139753820834074104124147
failure1558538208322546781117137170
and174253820833471108
death186453820834175105125162
in204053820831854
patients21085382083417393107141177197224
initiated2346538208317546788102133153185224
on258453820834077
sodium­267553820832965104117153210230
‑glucose4255482083216074110141176202235
cotransporter-26745482083306586106137174199237274294317350370388417
inhibitors11055482083145087100138152173209229255
versus13745482083306383109144169
other15575482083365693127147
glucose‑lowering17185482083365086117152178211233248285334367387402438476
drugs:22085482083365693130155166
The238854820833169103
CVD‑REAL250554820833875120143178211252283
study2801548208325478342555820833869
(Comparative5085582083165389146184215235267287301332365
Effectiveness887558208330476699131153167198231268301327352
of125355820833553
Cardiovascular13195582083386989126139176207238263294331344375395
Outcomes172855820834481103132167224258283
in202555820831249
NewUsers208855820834275125180205238258284
of238655820833452
Sodium‑Glucose245255820833067105119155211232277292328359394420453
Cotransporter-24255682083407696116148184209247284304328360380398428
Inhibitors).8675682083135086100137152173208228254270280
Circulation.11605682083395373102139153183204218254291303
2017;136(3):249-259.14775682083336596124132161189222240272288298332363394417446480511520
17.4255781085366674
Kosiborod5125782083377399112150187207243281
M807578208357
et87857820833556
al.9485782083344859
Cardiovascular10215782083427493130144180211242268298335349380399
Events14345782083356598135155181
Associated16295782083436995131163176207227260298
With19415782083597495132
SGLT-2208757820833477107135152182
Inhibitors22835782083165389103141155176212232258
Versus25555782083376888114150175
Other274457820834971108141161
Glucose‑Lowering4255882083445894125161186220241273309359392411426462500
Drugs:93958820834363100138163174
The112758820833068101
CVD‑REAL124258820833875121143178211252282
21538588208332
Study.15845882083315087125155164
Journal17625882083225995115152183197
of197358820833553
the20405882083205790
American214458820833995129149163194225262
College24205882083387388101135173206
of264058820833653
Cardiology.270758820833870891261401764255982083155290120129
2018;71(23):2628-2639.5685982083336596125136168199212245278294304338370402435456486518550582592
18.30471581085366985
Udell314815820834584119134150
JA331315820832565
et339315820833558
al.34661582083334861
Cardiovascular35431582083407394133148186218251277309347363395416
outcomes39741582083397799130167225260287
and427615820833371110
risks4402158208321376393122
after45391582083335277111132
initiation4686158208316546991107139160176214252
of495315820833958
a5026158208333
sodium507415820832866105121158216
glucose53051582083395592124161188223
cotransporter30471681083316889110143181207245284305330363384
23446168108332
inhibitor:34931681083124987102141156178215236250
Results37581681083326794130145168195
from39681681083163875132
the41161681083195691
EASEL422216810833073106138169
population‑based440616810833675114152167199220235273311333373406432467506
cohort492716810832865103141162187
study51291681083234684123154
(evidence5298168108316498196135169207304717810833165
for31271781083165375
cardiovascular32171781083296182120135173205238264296334349381402
outcomes36341781083357395126163221256282
with39321781083486385123
sodium407117810832361101116153211
glucose42971781083355188120157183218
cotransporter45301781083296688109142179206244283305329363384
24929178108332
inhibitors49761781083125088103142157179216237265
in525617810831250
the53211781083195792
real5428178108318528499
world).304718810835188110126165184195
Circulation.32571881083405677108146161193215230268307320
2018;137(14):1450-1459.359218810833468100131143173203235252283315332344374405438472496526557590623633
19.30471980085366983
Patorno31461981083346688126148187226
E3388198108331
et343419810833355
al.35051981083304660
Empagliflozin358119810833189128162201217233251268307335351390
and398719810833068108
the41111981083205894
Risk42211981083334976106
of434319810833656
Heart441519810834277110131157
Failure4588198108330607692130151186
Hospitalization479019810834281108148164187220236252281315337353392431
in523719810831351
Routine530419810833372111134150188224
Clinical30472081083395570107122154187202
Care:32652081083376991124137
A3417208108339
First3471208108330456693116
Analysis360320810833876108123155182197223
from38412081083163875133
the39902081083195791
EMPRISE409720810833085120155171203235
Study.43472081083305189128159170
Circulation.45322081083375374105142157189211227264302316
2019;139(25):48632081083326697127140170200233252286320339351
2822-2830.52292081083326599133153184218251286298
20.30472180085367388
McMurray315121810835588144182204226260292
JJV34592181083234886
et356121810833356
al.36342181083314761
Dapagliflozin371121810834578118151191207223241258297326342381
in410821810831453
Patients41772181083346789105141180202230
with44232181083516790129
Heart456821810834479112134159
Failure4743218108332627894132154189
and494821810833270110
Reduced507421810833571111149182217257
Ejection53472181083324883117142158304722820833776
Fraction.31392282083335488120145161200239253
N3408228208345
Engl346922820833472112128
J3613228208325
Med.365422820835591131145
2019;381(21):1995-2008.381522820833570102133146182217250266300332347360391421457492515547581618654669
21.30472380085367083
Abraham314623820834181103137176209267
WT342923820835795
et354023820833356
al.36122382083314861
Rationale36892382083356891107146185218234269
and397423820833270110
design410023820833873101116156195
of431123820833656
the43842382083216095
EMPERIAL‑Preserved449523820833288125158194210252285301338360394422458480515550590
and510123820833270110
EMPERIAL­522723820833288125158194210252285300
‑Reduced30472482083215994135173206240280
trials3343248208325476496112139
of349824820834060
empagliflozin357424820833796136170209225241259276315344360399
in398924820831856
patients40612482083427698114150188211239
with43162482083547093132
chronic44642482083347395133172188220
heart470024820834177109131156
failure.4872248208322567288126148182195
European50832482083367395133173210242281
Journal53802482083276610512730472582083387187
of315025820833858
Heart322425820834480113135160
Failure.3400258208333637995133155190203
2019;21(7):932-942.361925820833469102133146182214230265285298334367400421457494527540
22.30472680085367390
Packer315326820833567100131166188
M3357268208354
et342726820833356
al.34992682083314761
Cardiovascular35762682083397294133149188220254281314352369401423
and401526820833170110
Renal414126820833570109142158
Outcomes431526820834686109140178237273300
with46312682083506689128
Empagliflozin477526820833290130164204220235254271310338355393
in518426820831453
Heart525326820834379112134159
Failure.5428268208331627730472782083155375110123
New318627820834581133
England333527820833371111127160199238
Journal358927820832564103125164197213
of381827820833858
Medicine.389227820835691132147180196234270283
2020;383(15):1413-1424.419127820833570103138152187222257276308339358371401433464495517549580614646660
23.30472880085367288
Anker315028810833977108142164
SD332928810833176
et342128810833154
al.34912881083294559
Empagliflozin356528810833188128161200216231249266304333349387
in396828810831250
Heart403428810834277109131156
Failure4205288108331607691129151185
with44062881083486487125
a4547288108329
Preserved45922881083335488116151172207242281
Ejection48892881083314681114138154192231
Fraction.51362881083305083116140156194232246
New539828810834278129
England304729810833371111127160198238
Journal330129810832564103125164197213
of353029810833858
Medicine.360429810835591131147180196234270283
2021;385(16):1451-1461.390329810833569103135144180215250268300332351364394426459491510542574611641652
24.30473080085367187
Voors315030820833774113135163
AA332930820834286
et343130820833558
al.35053082083324862
The358330820833373109
SGLT2370830820833378111141177
inhibitor39013082083165493109149165188226248
empagliflozin416530820833593133167207223238257274313341358396
in457730820831654
patients46473082083407496112147186209237
hospitalized490030820833877105144161184217233249279314354
for52703082083195780
acute536630820833265104127161
heart304731820833873106128153
failure:3216318208319536985123145180193
a3425318208332
multinational347331820835897113136152190223246262301340373389
randomized38783182083215594133172231247277311352
trial.4246318208322446193109123
Nature438531820834578101140161196
Medicine.459731820835591131147180196234270283
2022.489631820833569103138152
25.30473280085367388
Herrington315132810834278100122138176216239276315
WG348232810835599
et359732810833255
al.36683281083304659
The374332810833170106
potential38643281083377699133172194209242258
for41373281083175577
improving423032810831371110132170203219257296
cardio‑renal45423281083306385123139177201224258297330346
outcomes49033281083367497128166224260287
by520632810833768
sodium­529032810832463103119157215238
‑glucose30473381083216278116149187214250
co‑transporter-233133381083326993116139172211238278317339365399421442473
inhibition38023381083155493109148165188204242282
in410033810831553
people416933810834076115156172208
with43933381083516790129
chronic45383381083327193130170185218
kidney47723381083304787126161194
disease:49823381083385481117149176212225
a5223338108333
rationale5272338108321557793132171204220255
for30473482083185779
the31423482083226197
EMPA‑KIDNEY325534820833389126164186223240287333367405
study.36763482083265089129161172
Clinical38643482083415772111127159193209
Kidney40893482083355392131167199
Journal.430434820832564102124164197213226
2018;11(6):749-761.454634820833570103134147178206222256275287321353386411443475506516
26.30473580085367288
Jardine31513581083235577115131169205
MJ337235810835279
et346635810833355
al.35373581083304660
The361235810833171106
Canagliflozin373435810833872110143182198214232249287316332370
and412035810833069108
Renal424435810833369107140156
Endpoints441635810833169108148187203242264292
in472435810831251
Diabetes47913581083435992131167190224252
with50583581083496588127
Established52013581083305882115155171187213252287327
Nephropathy304736810834580120159181218259292314353384
Clinical34473681083385470108124156190206
Evaluation36693681083316396112150183206221260299
(CREDENCE)39843681083175693127173207252293327347
study43473681083244887126159
rationale,4522368108319527590129168201217252265
design,48033681083367199114154192205
and502436810833069109
baseline51483681083377198134150165204239
characteristics.54033681083306810130473781083215487112146168185212235251284312327
American3390378108341100136158174207240279
journal36853781083165493115154187204
of390537810833858
nephrology.397937810833873113153174212229268308341352
2017;46(6):462-472.434737810833469102132142178214234268287300335371405427464497532545
27.30473880085367281
Heerspink314438820834580116138166206222261292
HJL345238820834470102
et357138820833457
al.36443882083314861
Dapagliflozin372138820834679118152192208224242259298327343381
in411838820831554
Patients41883882083356890106142180203231
with44353882083516790129
Chronic458038820834079100138178193226
Kidney48223882083355292130166198
Disease.50363882083466289125157184220233
New528538820834581132
England54333882083337230473982083385487126165
Journal322839820832564103125164197213
of345739820833858
Medicine.353139820835691132147180196234270283
2020;383(15):1436-1446.383039820833570103138152187222257276308339358371401433466501526557589626663677
28.30474080085367288
McMurray315140810835285140178199222255286
John345240810832261100138
JV360540810832260
et368040810833255
al.37504081083304659
Effects38254081083304968103136160188
of402940810833554
Dapagliflozin409940810834375115148187203218236253291319335373
in448840810831351
Patients45544081083336587103138176198226
With47964081083557194132
Kidney49444081083334988126162193
Disease,51534081083435985120152179214227
With53954081083557295133
and304741810833271110
Without31734181083587598137176215238
Heart342741810834581113135161
Failure.3604418108333637995133155189202
JACC:382241810832566106145158
Heart399741810834480113134160
Failure.4173418108333637995133155190202
2021;9(11):807-820.439141810833570104136145181201233262277289325361394413450484519532
29.30474280085367287
Davies314942810834477109125160188
MJ335342810835279
et344842810833255
al.35194281083304659
Management359442810835386124157197232291326365387
of399742810833555
hyperglycaemia406842810833667108144166204220252284318353412427460
in454442810831351
type46114281083205495131
24758428108332
diabetes,48064281083365285125161184218245259
2018.50814281083326799131145
A5242428108339
consensus52974281083296710613316820730474381083266491
report31544381083225696136158184
by335443810833971
the34414381083236297
American3554438108342101137159175208241280
Diabetes38504381083466395135171194229256
Association41224381083427198137171186219241257296335
(ADA)447343810832062108149168
and465743810833372112
the47854381083226197
European48984381083347193131171207240278
Association51924381083427198137171186219241257296335
for30474482083185779
the31424482083226197
Study32554482083335594133166
of343744820833858
Diabetes35114482083466295135171194229256
(EASD).37834482083195396131177195207
Diabetologia.40064482083466295135171194232248287327343376390
2018;61(12):2461-2498.441244820833569102134147183214230262293311324360392429460480511544578613627
30.30474580085367389
Buse315245820833978105140
JB330845820832865
et338945820833760
al.34654582083355165
2019354645820833772105135
update369845820834080120153176210
to:39244582083256376
Management401645820835891130163202238296332371393
of442545820834161
hyperglycaemia450245820834172113149171210226258290324360418434467
in498545820831856
type505745820832560100137
25210458208337
diabetes,52634582083425890130166189224251265
2018.304746810833570103135150
A3213468108348
consensus327746810833876116144180219247286313
report360746810832662102143166191
by381546810834577
the390946810832867104
American4029468108348107144166183216250290
Diabetes433546810835269102142179203238266
Association461746810834877105145179195228251267307347
(ADA)498046810832567115156176
and517246810833978118
the530746810832867104
European54274681083397730474781083215999135168206
Association32694781083427098136170186218241257295335
for36204781083185779
the37154781083226196
Study38274781083335594133166
of400947810833858
Diabetes40834781083456294134170193228255
(EASD).43544781083195396131177195207
Diabetologia.45774781083456194134170193231248286327343375389
2020;63(2):221-228.498247810833569103138151188222241276294307343378410430461497531545
31.30474880085367083
ADA,314648820834490131145
Standards33074882083355791129169202224263290
of361348820833959
Medical368848820835793133149182215231
Care39354882083437698133
in408448820831756
Diabetes–2022.41564882083476496136172195230257294326361394430443
Diabetes46154882083486497136173196230258
Care.48894882083427697132145
2021.505048820833771105137147
45(Supplement_1)52134882083377089121159199239256291304749820835793132154192225240
32.30475080085367288
Cosentino315150810834684112147186209225263303
F3470508108338
et352450810834063
al.36035081083385468
2019368750810834075107138
ESC384150810833974115
Guidelines397250810835089105144180196212251287314
on430350810834382
diabetes,44015081083446093133169192227255268
pre‑diabetes,468650810834466101125166182215255291315349377391
and509350810833776116
cardiovascular5225508108337719313214818722025328130475181083317086119140
diseases32045181083405683119151179214242
developed346251810834176109144161199240276316
in379451810831856
collaboration38665181083347288104137177217239273295311350389
with42715181083537093132
the44195181083246399
EASD:453451810833578113159173
The472351810833575111
Task48505181083356491122
Force49885181083357395127161
for51655181083216082
diabetes,52635181083415789129166189223251264
pre‑diabetes,30475282083396196120161177209249285308343370384
and344752820833271111
cardiovascular35745282083316587125141180213246274307345361394416
diseases40065282083385481117149176212240
of426252820833757
the43355282083226197
European44485282083337092130170206239277
Society474152820833372106121157180214
of497152820833858
Cardiology50455282083407495134150189205244284317
(ESC)53785282083195387128150
and304753820833271110
the31735382083246399
European32885382083357294132172209241280
Association35845382083437299138171187220242258297336
for39365382083215982
the40345382083246398
Study41485382083355796136168
of433253820834060
Diabetes44085382083486497137173196230258
(EASD).46825382083215498133178197208
European49065382083357394132173209241280
Heart520253820834783115137162
Journal.53805382083276610512730475482083387187100
2019;41(2):255-323.316354820833570102133147182213229264282295331366399422455489524537
33.30475580085367287
Authors/Task315055820834179102141180202230257294323350381
Force35475582083327093124159
M3722558208354
et379255820833457
al.38655582083324862
2021394355820833469102134
ESC409355820833368109
Guidelines42185582083448298138173190205244280307
for45415582083195779
the46365582083226196
diagnosis47485582083395487127166205232247274
and503855820833271111
treatment51655582083214378111133192228267289
of547055820833757
acute304756820833265103126161
and322456820833170110
chronic33505682083316991129168184217
heart358356820833773105127152
failure:3751568208318526884122144179192
Developed395956820834581114149165204245281321
by429656820833870
the43825682083226196
Task44945682083326188119
Force46295682083327092124159
for48045682083185678
the48985682083216096
diagnosis50105682083385486126165204231247274
and530056820833170109
treatment54265682083214378304757820833254113149188210
of327357820833858
acute334757820833265103126161
and352457820833271111
chronic36515782083317092130169185217
heart388457820833874106128154
failure4054578208318526884122144179
of424957820833858
the43235782083226196
European44355782083337193130171207240278
Society472957820833372106121157180214
of495957820833858
Cardiology50335782083407496135150189206245285318
(ESC).53675782083195287128149161
With30475882083577497136
the319958820832766102
special331758820833171107141157189205
contribution353858820833775114136158174214253276292331370
of392458820834363
the400358820832766101
Heart412058820835086118140165
Failure4302588208337678399137159194
Association451258820834675102141175190223245261300339
(HFA)486758820832469103142161
of504458820834363
the512358820832766102
ESC.524158820833872113127
Eur53845882083387697
J5497588208330
Heart304759820834480112134160
Fail.3223598208333637995108
2022;24(1):4-131.334759820833570103139152188220240273288300336359391421453463